Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Abbott - LARVOL DELTA

Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis. (PubMed, Diabetes Care) - "Although more evidence is needed, continuation of semaglutide after dialysis initiation appears safe and warrants efficacy testing regarding reduction in MACE and death."

Journal • Retrospective data • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Renal Disease • Type 2 Diabetes Mellitus

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) (clinicaltrials.gov) - P3 | N=1840 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study. (PubMed, Diabetes Obes Metab) - "Semaglutide 2.4 mg was associated with a significantly reduced risk of MACE and other obesity-related outcomes, extending prior evidence of benefits to a broader clinical ASCVD population."

Journal • Real-world evidence • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Myocardial Infarction • Obesity • Type 2 Diabetes Mellitus

Wegovy Pill and Wegovy Pen Now Available with Hims & Hers - "...Hims & Hers is offering direct access to Wegovy pills, Wegovy injections and Ozempic injections at all dosage levels. With cash-pay prices starting at $149 a month..."

Commercial • Obesity

REAL-WORLD EFFECTIVENESS OF SEMAGLUTIDE AND SGLT-2I VS SGLT-2I ALONE ON KIDNEY AND CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (ISN-WCN 2026) - "Negative control outcome analyses indicated no unmeasured confounding (RR for any fractures, 1.02 [0.95, 1.11], p=0.49).Download: Download high-res image (100KB)Download: Download full-size imageDownload: Download high-res image (90KB)Download: Download full-size imageDownload: Download high-res image (103KB)Download: Download full-size imageConclusion This study suggests that combination therapy with semaglutide + SGLT-2i provides kidney and cardiovascular benefits compared with SGLT-2i alone among people with T2D and CKD.I have potential conflict of interest to disclose.ELF has been supported through personal grants awarded to his institution from the Dutch Kidney Foundation (22OK2026), Dutch Research Council (09150162310058) and Leiden University Medical Center; received honoraria for lectures from Aarhus University and Japanese Society of Nephrology; and travel support from the European Renal Association, National Kidney Foundation and KDIGO, all unrelated to the..."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Heart Failure • Metabolic Disorders • Musculoskeletal Diseases • Myocardial Infarction • Nephrology • Orthopedics • Renal Disease • Type 2 Diabetes Mellitus

EFFECT OF ONCE-WEEKLY SEMAGLUTIDE 1.0 MG ON KIDNEY OUTCOMES BY BASELINE CHARACTERISTICS: EXPLORATORY DATA FROM THE FLOW TRIAL (ISN-WCN 2026) - P3 | "A considerable proportion of participants were receiving metformin (51.9%) and insulin (61.4%) at baseline.The benefit of semaglutide on the 4-component kidney-specific composite outcome was consistent across most baseline subgroups including sex (interaction p value [pint]=0.1557), race (pint= 0.4812), HbA1c (pint=0.4941), retinopathy status (pint=0.4927) and diuretic use (pint=0.2503) (Fig). No heterogeneity was observed for the effect of semaglutide on kidney failure across any of the baseline subgroups.Conclusion In the FLOW trial, the benefit of semaglutide on key kidney outcomes was generally consistent across baseline subgroups, with the exception of diabetes duration 15 years which requires further study.Download: Download high-res image (361KB)Download: Download full-size imageFigure. Subgroup analyses of the 4-component, kidney-specific composite outcome by baseline characteristics."

Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Retinal Disorders

MECHANISTIC EFFECTS OF SEMAGLUTIDE ON KIDNEY DISEASE IN TYPE 2 DIABETES: THE REMODEL TRIAL (ISN-WCN 2026) - "Semaglutide reduced the renal arterial resistive index (ETR 0.96, 0.93-0.99), while cortical oxygenation (ETR 0.98, 0.96-1.01) and perfusion (ETR 1.10, 0.98-1.24) trended higher (Figure 1C). In the biopsy subset (N=33), the arteriolar intimal area of the most diseased vessel decreased by 10%, and glomerular endothelial-cell transcriptomes revealed downregulation of genes in metabolic, inflammatory, and fibrotic pathways by semaglutide (Figure 1D).Download: Download high-res image (205KB)Download: Download full-size imageConclusion In participants with T2D and CKD, semaglutide reduced kidney fat, improved glomerular hemodynamics, and ameliorated endothelial injury through metabolic reprogramming and mitigation of inflammation and fibrosis.This abstract was also submitted for the ASN congress.I have potential conflict of interest to disclose.NB is employee of and owns shares in Novo NordiskI did not use generative AI and AI-assisted technologies in the writing process."

Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial. (PubMed, JAMA Cardiol) - P3 | "In this post hoc secondary analysis of the SOUL randomized clinical trial, oral semaglutide was associated with early and sustained improvements vs placebo in multiple ASCVD risk factors in high-risk participants with T2D and ASCVD and/or CKD, incremental to SoC. ClinicalTrials.gov Identifier: NCT03914326."

Clinical • Journal • Retrospective data • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Diabetes • Dyslipidemia • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • CRP

Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real-World Evidence From the REALISED Study. (PubMed, Diabetes Obes Metab) - "The REALISED study provides the first real-world evidence of the use of oral semaglutide in Thai patients with T2D, demonstrating significant improvements in glycaemic control and weight reduction across routine care settings."

Clinical data • HEOR • Journal • Real-world evidence • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. (PubMed, Lancet) - P3 | "Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease. Safety and tolerability of semaglutide in early Alzheimer's disease is consistent with studies in other indications."

Journal • P3 data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Patients with Type 2 Diabetes in Finland (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Real-world • Real-world evidence • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparing Major Adverse Kidney Events (MAKE) among New Users of Oral Semaglutide (SEMA) vs. Select Oral Antidiabetic Medications (ADMs) among U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Adverse events • Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China. (PubMed, Diabetes Ther) - P | "Initiating once-weekly semaglutide was associated with significant improvements versus baseline in glycemic control and lipids in people with T2D from Tianjin, China. Safety of semaglutide was similar to the established safety profile per adverse events assessment."

Journal • Real-world evidence • Constipation • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

The US Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk over failures in reporting suspected adverse side effects linked to the GLP-1 drugs Ozempic and Wegovy. (CNBC-TV18) - "In the letter and an accompanying inspection report, the FDA said Novo Nordisk did not report all suspected side effects in patients taking Ozempic. The agency said the cases included two deaths and a suicide....FDA investigators at the company’s US headquarters in Plainsboro said they found more than 300 adverse event reports that had not been submitted to the agency. Some reports were more than 1,000 days late. The cases included at least four deaths and a suicide. The FDA said the company did not promptly investigate a report in which a doctor told a company representative that a patient taking semaglutide was depressed and later committed suicide."

FDA event • Obesity • Type 2 Diabetes Mellitus

Novo Nordisk ​said on Monday it will sell its blockbuster Wegovy and Ozempic drugs through the U.S. telehealth company Hims & Hers Health (HIMS.N), opens new tab platform, ‌ending a legal dispute that erupted last month. (Reuters) - "Under the agreement, Hims will offer approved Ozempic and Wegovy injectables, as well as the Wegovy pill, to U.S. consumers on its platform at ​Novo's self-pay prices. Hims had a short-lived agreement with Novo in 2025 to sell branded Wegovy. Hims will no longer advertise compounded GLP-1 drugs, though it will ​continue offering them when providers deem it clinically necessary. U.S. regulations allow companies to sell compounded versions of drugs in personalized doses not available in the branded forms, or with special ingredients....Novo Nordisk CEO Mike Doustdar said the Wegovy pill had generated more than 600,000 prescriptions since its launch two months ago, with telehealth partnerships accelerating uptake."

Commercial • Obesity

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes (clinicaltrials.gov) - P4 | N=300 | Recruiting | Sponsor: The University of Texas Health Science Center, Houston | Trial completion date: Jul 2026 ➔ Oct 2026 | Trial primary completion date: Nov 2025 ➔ Oct 2026

Biomarker • Trial completion date • Trial primary completion date • Metabolic Disorders • TCF7L2

India's drug regulator CDSCO approved Orlistat, Tirzepatide, and Semaglutide for prescription weight loss treatment. (ThePrint) - "All drugs intended for therapeutic use, including those claiming to reduce weight or modify metabolic rate, are required to comply with safety, quality and efficacy requirements under the New Drugs and Clinical Trials Rules, 2019, before approval for production, import or marketing, Patel told Rajya Sabha in a written reply...All drugs should be used in accordance with recommendations for use and under medical supervision, Patel stated...The state licensing authorities are empowered to take action on violations of any conditions of such licenses....As per the conditions of license, sales of drugs shall be effected only by or under the personal supervision of a registered pharmacist and no person can sell 'the Schedule H, H1 and X drugs without prescription of a registered medical practitioner (RMP)'."

Commercial • Obesity

GLP-1 RECEPTOR AGONIST-INDUCED SINUS TACHYCARDIA MIMICKING ARRHYTHMIA IN A PATIENT WITH AN IMPLANTED LOOP RECORDER (ACC 2026) - " 70-year-old man with type 2 diabetes mellitus, hypertension, and prior transient ischemic attack was initiated on semaglutide (Ozempic®) for glycemic optimization... This case underscores the potential for GLP-1 RAs to cause sustained sinus tachycardia, which may mimic pathologic arrhythmia and prompt unnecessary invasive monitoring. Clinicians should recognize this rare adverse effect to avoid unwarranted procedures and guide appropriate management."

Clinical • Atrial Fibrillation • Cardiovascular • Diabetes • Endocrine Disorders • Heart Failure • Hematological Disorders • Hypertension • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=465 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus • CST3 • EGFR

WAYS TO OVERCOME CHALLENGES IN GLP USE IN TYPE 1 DIABETES (ATTD 2026) - "These include: Metformin,Coleselvelam, Dipeptidyl Peptidase-4 Inhibitors (DPP-IVinhibitors), Sodium-Glucose Cotransporter 2 inhibitors(SGLT-2is), daily or weekly Glucagon-Like Polypeptides(GLPs), with or without Glucose-Dependent InsulinotropicPolypeptide (GIPs)-dual incretin.(11-15) These medicationshave benefits beyond glucose control that include: weightloss, protections from cardiovascular disease (CVD), and diabetickidney disease (DKD)...The only other medication that wasapproved by the Food and Drug Administration (FDA) waspramlintide (Symlin®), which is hardly used in clinical practicebecause of the gastrointestinal (GI) side-effects, frequencyof injections per day and the increased risk of severehypoglycemia and ketosis...Both semaglutide(Ozempic®/Wegovy®, Copenhagen, Denmark) and tirzepatide(Mounjaro®/Zepbound®, Indianapolis, IN) weekly GLPanalogs are the preferred options for use in patients withT1D...There was recent FDA approval..."

Cardiovascular • Chronic Kidney Disease • Constipation • Diabetes • Diabetic Nephropathy • Diabetic Retinopathy • Fibrosis • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Obesity • Pancreatitis • Renal Disease • Retinal Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • TINCR

Ischemic Optic Neuropathy With Semaglutide: Global Observational Analysis of Sex- and Formulation-specific Risk (AAN 2026) - "Objective: We conducted the first global, population-based observational study of over 30 million reports to compare ischemic optic neuropathy (ION) risk with semaglutide formulations across diabetes and obesity...Comparator drugs were metformin, insulin, and tirzepatide... Overall, ION risk appears dose- and formulation-dependent, highest with Wegovy. Although Wegovy produced fewer ION reports than Ozempic, its lower overall reporting yielded a higher ROR."

Clinical • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • ROR1

SHORT-TERM COST AND HEALTH OUTCOMES COMPARISON OF SEMAGLUTIDE VERSUS TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA (ISPOR 2026) - "Within the context of financial sustainability challenges in Colombia, semaglutide demonstrated more favorable short-term economic value compared with tirzepatide. These findings provide actionable evidence to inform HTA processes, reimbursement decisions, and evidence-based guideline positioning in Colombia and similar middle-income settings."

Clinical • HEOR • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Myocardial Infarction • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Semaglutide Hype or Hope: Evidence-based Review in Diabesity. (PubMed, J Assoc Physicians India) - "Gastrointestinal side effects are the most common adverse events seen with the molecule, as with other GLP-1 drugs. This review highlights the global clinical data and practicalities of the use of Ozempic in diabesity in the Indian context."

Journal • Review • Cardiovascular • Diabetes • Metabolic Disorders • Peripheral Arterial Disease • Type 2 Diabetes Mellitus

SEVERE INSULIN RESISTANCE IN TYPE 2 DIABETES SUCCESSFULLY MANAGED WITH MEDTRONIC 780G CLOSED-LOOP SYSTEM: A CASE REPORT (ATTD 2026) - "Her regimen included high-dose rapid-acting insulin lispro U-200, long-acting insulin glargine U-300 (Toujeo), maximum-dose metformin (1000 mg BID), and once-weekly semaglutide (Ozempic) at 1.2 mg. This case highlights the potential role of advanced diabetes technologies such as the Medtronic 780G closed-loop insulin delivery system in managing extreme insulin resistance in type 2 diabetes. Even in cases with longstanding hyperglycemia and high insulin requirements, automated insulin delivery can significantly improve glycemic control and reduce insulin needs. This supports broader consideration of insulin pump therapy in selected patients with refractory type 2 diabetes."

Case report • Clinical • Acromegaly • Cushing’s Disease • Diabetes • Endocrine Disorders • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

PI24/01356: Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i (clinicaltrialsregister.eu) - P4 | N=60 | Sponsor: Fundacio Hospital Universitari Vall DHebron Institut De Recerca

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus